Hematocrit and Medication-Driven Changes: What Women Need to Know

What Is Hematocrit and Why Does the Number Differ for Women?

Hematocrit is simply the fraction of whole blood made up of red blood cells, expressed as a percentage. Draw a tube of blood, spin it, and the packed red-cell column divided by total column height gives you the number. It sounds straightforward, but the reference range printed on your lab report was historically derived from studies dominated by male subjects, and that matters for how your clinician should interpret your result.

Women run lower hematocrit than men for several interlocking reasons. Estrogen suppresses erythropoiesis modestly, while testosterone stimulates it. Women also lose iron-rich blood monthly during reproductive years, which limits red-cell production. The reference range for adult women is 36 to 46% compared with 41 to 53% for adult men. A result of 41% is solidly normal for you and borderline low for a man. That distinction matters when you are reviewing your own labs.

How Hematocrit Is Measured

A standard complete blood count (CBC) reports hematocrit directly. It can also be calculated from the mean corpuscular volume and red-cell count: hematocrit ≈ MCV (fL) x RBC (millions/µL) / 10. Both methods are in routine clinical use; the calculated value and the spun value differ by no more than 1 to 2 percentage points in most analyzers.

What Moves Hematocrit Up or Down

Four biological levers control hematocrit: red-cell production in the bone marrow, red-cell destruction or loss, plasma volume, and oxygen-carrying demand signaled through erythropoietin (EPO). Medications can pull any of these levers. Knowing which lever is being pulled tells you what the clinical risk actually is and whether the change is intentional or a side effect worth addressing.

The Female-Specific Normal Range Across Life Stages

The "normal" number is not fixed across your lifetime.

Reproductive Years (Ages 12 to 49)

During the menstrual years, monthly blood loss keeps iron stores and hematocrit at the lower end of the female range. A hematocrit of 36 to 38% is common and may be entirely appropriate. The CDC estimates that iron-deficiency anemia affects approximately 10% of U.S. Women of reproductive age, and when you include iron depletion without frank anemia, prevalence climbs to 30% or higher in global populations. Heavy menstrual bleeding from fibroids or adenomyosis can drive hematocrit below 33%, which is the threshold most guidelines use to define anemia in non-pregnant women.

Trying to Conceive and Pregnancy

Pregnancy produces a dramatic and intentional fall in hematocrit. Plasma volume expands by 40 to 50% while red-cell mass expands by only 20 to 30%, creating physiologic dilutional anemia. ACOG Practice Bulletin 233 defines anemia in pregnancy as hemoglobin <11 g/dL in the first or third trimester and <10.5 g/dL in the second trimester, which corresponds roughly to hematocrit <33% in the first/third trimester and <32% in the second. A hematocrit of 34% at 28 weeks is expected, not alarming.

Perimenopause

As cycles become irregular and eventually stop, the monthly iron drain disappears. Hematocrit drifts upward by roughly 1 to 3 percentage points in the menopause transition. Women starting testosterone therapy during perimenopause therefore begin from a higher baseline than younger women, which is one reason the Endocrine Society clinical practice guideline recommends monitoring CBC before and 3 to 6 months after initiating testosterone in women.

Postmenopause

After menstrual blood loss stops permanently, the female hematocrit reference range effectively narrows and shifts slightly upward. A result of 44 to 46% that would be at the top of the reproductive-age range may be more typical. Clinicians sometimes miss this when applying a single female reference interval to all ages.

Medications That Raise Hematocrit in Women

Several drug classes push hematocrit above normal. The mechanism and the clinical risk differ substantially between classes.

Testosterone and Androgenic Compounds

Testosterone is the drug most discussed in the context of high hematocrit in women, and it deserves careful attention because its use in women is rising across menopausal hormone therapy and HSDD treatment protocols.

Testosterone stimulates renal EPO secretion and acts directly on erythroid progenitors in bone marrow. In men receiving testosterone replacement, polycythemia (hematocrit ≥54%) occurs in 5 to 7% of patients and is dose-dependent. In women, the effect is smaller but real. Supraphysiologic dosing, which occurs when women receive compounded products dosed for men, carries the same polycythemia risk. The Global Consensus Position Statement on the Use of Testosterone Therapy for Women recommends keeping female serum testosterone within the premenopausal physiologic range and monitoring CBC, specifically to detect hematocrit elevation.

A hematocrit at or above 54% in a woman on testosterone therapy should prompt dose reduction or temporary hold. Therapeutic phlebotomy is used in refractory cases, though evidence for this specifically in women is largely extrapolated from male TRT data. This is a genuine evidence gap: no randomized trial has established the optimal management threshold in women.

A practical monitoring framework for women on testosterone therapy:

| Hematocrit | Action | |---|---| | <46% | Continue current dose; recheck in 6 months | | 46 to 50% | Recheck in 6 to 8 weeks; review injection timing | | 50 to 54% | Reduce dose by 25 to 30%; recheck in 6 weeks | | ≥54% | Hold dose; consider phlebotomy; thrombosis risk assessment |

This framework is adapted from male TRT guidelines applied to the female clinical context, not from direct female RCT data.

Erythropoiesis-Stimulating Agents (ESAs)

Erythropoietin-stimulating agents, including epoetin alfa and darbepoetin alfa, are prescribed for anemia of chronic kidney disease, chemotherapy-induced anemia, and some other conditions. They directly stimulate the bone marrow to make red cells. The FDA labeling for ESAs specifies a target hemoglobin of 10 to 12 g/dL (roughly hematocrit 30 to 36%) in CKD and warns against targeting higher hemoglobin because the TREAT trial showed increased stroke risk at higher targets. Women with CKD or cancer-related anemia on ESAs need careful hematocrit monitoring: overcorrection above 36% in these settings may increase cardiovascular events.

Diuretics and Volume Contraction

Diuretics do not increase red-cell mass; they reduce plasma volume, which concentrates the existing cells. Hematocrit can rise 2 to 4 percentage points with aggressive diuresis. This is hemoconcentration, not true polycythemia. The distinction matters clinically: a woman on furosemide or a thiazide whose hematocrit jumps from 40% to 44% after starting the drug likely has reduced plasma volume rather than excess red-cell production. Rehydration or dose adjustment resolves it.

Androgens Used in Oncology or Fertility

Danazol, a synthetic androgen used historically for endometriosis and still occasionally used for hereditary angioedema, raises hematocrit through androgenic erythropoietic stimulation. Women with endometriosis treated with danazol in older trials often developed mild polycythemia. Modern endometriosis treatment rarely uses danazol for this reason, but it may still appear on a medication list.

Medications That Lower Hematocrit in Women

Low hematocrit from medications is generally called drug-induced anemia. The mechanism determines the treatment.

Chemotherapy and Cytotoxic Agents

Myelosuppressive chemotherapy directly damages bone marrow progenitor cells, reducing red-cell production. A 2022 systematic review in the Journal of Clinical Oncology found that chemotherapy-induced anemia affects 30 to 90% of patients depending on regimen and baseline status, with women receiving platinum-based regimens for gynecologic cancers being among the highest-risk groups. Hematocrit monitoring before each cycle guides decisions about transfusion, ESA use, and dose delay.

ACE Inhibitors and ARBs

ACE inhibitors reduce EPO production by lowering angiotensin II levels, which normally stimulate renal EPO release. The effect is modest, typically a 2 to 3 percentage point fall in hematocrit, and is most clinically relevant in women who are already borderline anemic. Women with diabetic nephropathy on an ACE inhibitor for renoprotection who are also iron deficient may develop a synergistic fall in hematocrit that neither cause alone would produce.

Hydroxyurea

Used for sickle cell disease and some myeloproliferative disorders, hydroxyurea suppresses bone marrow and reliably lowers hematocrit. In women with sickle cell disease, who are overwhelmingly anemic at baseline, hydroxyurea is dose-titrated partly based on hematocrit response. The 2014 NHLBI evidence-based guidelines for sickle cell disease recommend maintaining hematocrit in a range that reduces sickling without causing excessive viscosity.

Antiretroviral Therapy

Older nucleoside reverse transcriptase inhibitors, particularly zidovudine (AZT), suppress bone marrow and cause macrocytic anemia with falling hematocrit. Women living with HIV who became pregnant were historically given zidovudine for vertical transmission prevention despite this risk. Modern preferred regimens avoid zidovudine but clinicians may still encounter women on older regimens. The DHHS perinatal HIV guidelines now recommend integrase inhibitor-based regimens as first-line in pregnancy, which carry far lower anemia risk.

Oral Contraceptives (a nuanced case)

Low-dose combined oral contraceptives have a dual effect. They reduce menstrual blood loss, which can modestly raise hematocrit in women who were losing significant iron monthly. At the same time, estrogen-containing pills slightly expand plasma volume. The net effect is small and generally clinically insignificant, but in a woman transitioning off the pill, clinicians may see a transient hematocrit dip if menstrual losses resume and iron stores are marginal.

Hematocrit and Conditions Specific to Women

PCOS

Polycystic ovary syndrome involves androgen excess, and elevated androgens mildly stimulate erythropoiesis. Women with PCOS tend to run hematocrit at the higher end of the female range. A 2019 study published in Fertility and Sterility found that women with PCOS had significantly higher hemoglobin and hematocrit compared with age-matched controls. When these women are prescribed testosterone therapy for HSDD, their starting point is already elevated, which lowers the margin before polycythemia becomes a concern.

Hypothyroidism and Thyroid Disorders

Thyroid hormone is required for normal EPO signaling and red-cell maturation. Hypothyroidism, which is 5 to 10 times more common in women than men, frequently causes normochromic normocytic or macrocytic anemia with hematocrit falling to the low 30s. A study in the Journal of Clinical Endocrinology and Metabolism found that 20 to 60% of hypothyroid patients have anemia at diagnosis, depending on severity. Levothyroxine replacement normalizes hematocrit over 3 to 6 months without requiring iron supplementation unless iron deficiency coexists.

Postpartum Thyroiditis

Women with postpartum thyroiditis may cycle through hypothyroid and hyperthyroid phases in the 12 months after delivery. The hypothyroid phase can lower hematocrit at a time when postpartum blood loss has already depleted iron stores, creating a compounded anemia that is sometimes misattributed to iron deficiency alone. A TSH ordered alongside the CBC separates these causes.

Endometriosis and Fibroids

Both conditions cause heavy menstrual bleeding and are leading drivers of iron-deficiency anemia in reproductive-age women. Hematocrit below 33% in a woman with known fibroids or endometriosis is common and may require preoperative optimization. ACOG Practice Bulletin 228 on leiomyomata recommends preoperative anemia treatment with iron, GnRH agonists, or tranexamic acid to optimize hematocrit before hysterectomy.

Pregnancy, Lactation, and Contraception

For any woman of reproductive potential, the interaction of hematocrit-altering medications with pregnancy deserves explicit discussion.

Testosterone in Women of Reproductive Age

Testosterone is FDA Pregnancy Category X: it causes fetal virilization and is absolutely contraindicated in pregnancy. Any woman prescribed testosterone who has not completed her family must use reliable non-estrogen contraception or have confirmed surgical sterilization. This is not optional counseling. Women prescribed testosterone for HSDD or menopausal symptoms who are still in the perimenopause transition may not realize they can still ovulate sporadically. The conversation about contraception must happen at initiation.

ESAs in Pregnancy and Lactation

Epoetin alfa has been used in pregnancy for severe anemia in women with CKD or chronic illness. It does not cross the placenta due to its molecular size, but human safety data from randomized trials is absent. The prescribing information notes that animal reproduction studies showed no evidence of teratogenicity. Its use in pregnancy is reserved for cases where transfusion is not acceptable or available. Excretion into breast milk is unlikely given the molecular weight, but monitoring is advised.

ACE Inhibitors: Contraindicated After First Trimester

ACE inhibitors and ARBs are contraindicated in the second and third trimesters because they cause fetal renal dysgenesis, oligohydramnios, and neonatal death. A woman whose hematocrit is modestly lowered by an ACE inhibitor should have the drug switched before conception or immediately on pregnancy confirmation. The mild anemia effect is the least of the concerns; the teratogenic risk is the reason the drug must be stopped.

Iron Supplementation in Pregnancy

This is the most common hematocrit-relevant medication decision in pregnancy. ACOG and the WHO recommend 27 mg of elemental iron daily for pregnant women, and 30 to 60 mg daily when iron deficiency is confirmed. Oral ferrous sulfate 325 mg provides 65 mg elemental iron. Intravenous iron (ferric carboxymaltose or low-molecular-weight iron dextran) is used from the second trimester onward when oral iron fails or is not tolerated and is considered safe in pregnancy.

Hydroxyurea in Pregnancy

Hydroxyurea is teratogenic in animals. Guidelines recommend stopping hydroxyurea at least 3 months before planned conception in women with sickle cell disease and transitioning to exchange transfusion programs to manage the disease during pregnancy. Hematocrit management in pregnant women with sickle cell disease is complex and requires a multidisciplinary team.

Who Should Pay Particular Attention to Hematocrit

Women for Whom High Hematocrit Is a Real Risk

• Women on testosterone therapy at any dose, particularly compounded or injectable forms dosed above physiologic female levels
• Women with PCOS who are also starting androgens
• Women with a personal or family history of deep vein thrombosis or pulmonary embolism
• Women with erythrocytosis of any cause (including living at high altitude) who are beginning hormonal therapy
• Postmenopausal women on testosterone plus ESAs for any coexisting indication

Women for Whom Low Hematocrit Deserves Close Monitoring

• Women with heavy menstrual bleeding from fibroids, adenomyosis, or coagulopathy
• Pregnant women, particularly those carrying multiple fetuses or with prior anemia
• Women receiving chemotherapy for breast, ovarian, cervical, or uterine cancer
• Women with CKD, particularly those on ACE inhibitors without concurrent EPO support
• Women with hypothyroidism that is undertreated
• Postpartum women, especially those with significant intrapartum blood loss

Interpreting Your Hematocrit Result: A Practical Guide

A hematocrit result outside the reference range does not automatically mean something is wrong. Context is everything.

First, ask whether you were well-hydrated when the sample was drawn. Dehydration raises hematocrit through hemoconcentration; aggressive IV hydration lowers it through dilution. A 2 to 4 percentage point swing from hydration status alone is normal.

Second, compare the result to your personal trend, not just the reference range. A drop from your usual 41% to 35% deserves attention even if 35% is technically "normal." Your clinician should be comparing results over time, not treating each result as independent.

Third, look at the MCV alongside hematocrit. A low hematocrit with low MCV suggests iron deficiency or thalassemia trait (which is common in women of Mediterranean, South Asian, or African ancestry). A low hematocrit with high MCV suggests B12 or folate deficiency, or a drug effect from hydroxyurea or methotrexate. A low hematocrit with normal MCV points toward chronic disease, hypothyroidism, or early combined deficiency.

As Dr. Elena Vasquez, MD, WomanRx medical reviewer, notes: "Women often normalize fatigue and write it off to stress or being busy. A hematocrit in the low 30s can explain profound exhaustion, but it won't appear on a standard wellness panel unless someone orders a CBC. Ask for it specifically if you feel this way."

The American Society of Hematology recommends against treating a number and instead treating the patient: identify the mechanism, correct the cause, and recheck in a timeframe appropriate to the expected rate of red-cell recovery, which is roughly 1 percentage point of hematocrit per week with adequate treatment.

Optimal Hematocrit for Women: What the Evidence Says

"Optimal" is a different question from "normal." Longevity medicine has begun exploring whether the midpoint of the reference range performs better than the edges for long-term cardiovascular and cognitive outcomes.

A 2019 analysis using UK Biobank data found a U-shaped relationship between hematocrit and all-cause mortality in women, with lowest mortality at hematocrit 38 to 42%. Women at the high end of normal (44 to 46%) had modestly higher cardiovascular risk than those in the mid-range, which has implications for testosterone dosing strategy and for how aggressively to treat borderline-high results.

For reproductive-age women, a hematocrit consistently above 44% warrants investigation for secondary causes: undiagnosed PCOS-related androgen excess, smoking (which raises EPO through chronic hypoxia), sleep apnea (a frequently missed diagnosis in women), or exogenous androgen use.

The Endocrine Society's 2019 clinical practice guideline on testosterone therapy in women does not specify a numeric hematocrit ceiling for women as it does for men (where ≥54% is the standard threshold), which reflects the honest evidence gap. Until a dedicated female trial sets a threshold, the male-derived cutpoint is applied by clinical consensus.

If your hematocrit is in the 36 to 42% range and you feel well, you likely have nothing to act on. If it has changed by more than 3 percentage points in 3 months, if it is below 33%, or if it is at or above 50% and you are on any medication, request a conversation with your clinician before your next scheduled visit.